Finally, some good news for Alimera (and pSivida). A few days ago, the company announced that it had received a positive outcome to the Decentralized Procedure (DCP) for Iluvien in Europe. Iluvien is now expected to be the first sustained release pharmaceutical in the European Union for the treatment of diabetic macular edema (DME).
The regulatory process will now enter the national phase of the DCP in which the Reference Member State (RMS), the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA), and each Concerned Member States (CMS) grants its national license. The CMS include Austria, France, (Read more...)